AI tool can predict Barrett's esophagus recurrence after therapy with 90% accuracy

A new artificial intelligence (AI)-based tool shows promise for improving surveillance in patients treated with endoscopic eradication therapies for Barrett's esophagus (BE)-related dysplasia and early esophageal adenocarcinoma. BE is the only known condition that precedes esophageal adenocarcinoma—an aggressive cancer with high mortality rates.